Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63: 11-30. 10.3322/caac.21166.
Article
PubMed
Google Scholar
Koul H, Huh JS, Rove KO, Crompton L, Koul S, Meacham RB, Kim FJ: Molecular aspects of renal cell carcinoma: a review. Am J Cancer Res. 2011, 1: 240-254.
PubMed
Google Scholar
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007, 356: 115-124. 10.1056/NEJMoa065044.
Article
CAS
PubMed
Google Scholar
Escudier B: Emerging immunotherapies for renal cell carcinoma. Ann Oncol. 2012, 8: 35-40.
Google Scholar
Palucka K, Banchereau J, Mellman I: Designing vaccines based on biology of human dendritic cell subsets. Immunity. 2010, 33: 464-478. 10.1016/j.immuni.2010.10.007.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D: Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer. 1999, 81: 1009-1016. 10.1038/sj.bjc.6690800.
Article
CAS
PubMed
PubMed Central
Google Scholar
Thanendrarajan S1, Nowak M, Abken H, Schmidt-Wolf IG: Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one?. Leuk Res. 2011, 35: 1136-1142. 10.1016/j.leukres.2011.05.005.
Article
CAS
PubMed
Google Scholar
Sun Y, Chen J, Cai P, Hu YH, Zhong GC, Feng HZ: Therapy of relapsed or refractory non-Hodgkin’s lymphoma by antigen specific dendric cells-activated lymphocytes. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010, 18: 219-223.
CAS
PubMed
Google Scholar
Yagoda A, Bander NH: Failure of cytotoxic chemotherapy,1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int. 1989, 44: 338-345. 10.1159/000281537.
Article
CAS
PubMed
Google Scholar
Hirschowitz E, Foody T, Hidalgo G, Yannelli J: Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer. 2007, 57: 365-372. 10.1016/j.lungcan.2007.04.002.
Article
PubMed
PubMed Central
Google Scholar
Yang B, Lu XC, Zhu HL, Han WD, Wang Y, Fan H, Li SX, Liu Y, Dai HR, Yao SQ: Clinical study of autologous cytokine induced killer cells combined with IL-2 for therapy of elderly patients with B-cell malignant lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010, 18: 1244-1249.
CAS
PubMed
Google Scholar
Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD: Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with ALdesleukin (Interleukin2) and IFN-α2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res. 2009, 15: 4986-4992. 10.1158/1078-0432.CCR-08-3240.
Article
CAS
PubMed
PubMed Central
Google Scholar
Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM: Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 2000, 8: 1928-1935.
Google Scholar
Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: mappingthe way. Nat Med. 2004, 10: 475-480. 10.1038/nm1039.
Article
CAS
PubMed
Google Scholar
Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M, Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN): Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol. 2004, 22: 1188-1194. 10.1200/JCO.2004.06.155.
Article
CAS
PubMed
Google Scholar
Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunothérapie. N Engl J Med. 1998, 338: 1272-1278. 10.1056/NEJM199804303381805.
Article
CAS
PubMed
Google Scholar
Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ: Activity of single-agent Bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. Clin Genitourin Cancer. 2013, 11: 45-50. 10.1016/j.clgc.2012.06.001.
Article
PubMed
Google Scholar
Bukowski RM, Eisen T, Szczylik C: Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol. 2007, 25: abstract5023-
Article
Google Scholar
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM: Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009, 27: 3312-3318. 10.1200/JCO.2008.19.5511.
Article
CAS
PubMed
Google Scholar
Maroto JP, Del Muro XG, Mellado B, Perez-Gracia JL, Andrés R, Cruz J, Gallardo E, Domenech M, Arranz JA, Meana JA: Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC). Clin Transl Oncol. 2013, [Epub ahead of print]
Google Scholar
Lesterhuis WJ1, Haanen JB, Punt CJ: Cancer immunotherapy--revisited. Nat Rev Drug Discov. 2011, 10: 591-600. 10.1038/nrd3500.
Article
CAS
PubMed
Google Scholar
Weber J: Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother Nat Rev Drug Discov. 2011, 10: 591-600.
Google Scholar
Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J: Improved endpoints for cancer immunotherapy trials. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010, 18: 1388-1397.
Article
Google Scholar
Knutson KL1, Disis ML: Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005, 54: 721-728. 10.1007/s00262-004-0653-2.
Article
CAS
PubMed
Google Scholar
Kraemer M, Hauser S, Schmidt-Wolf IG: Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells. Anticancer Res. 2010, 30: 2081-2086.
PubMed
Google Scholar